Skip to main content
Premium Trial:

Request an Annual Quote

SHORT READS: Oct 1, 2002 (rev. 1)

Premium

Marligen, a DNA analysis supply company, acquired Clairus Technologies, a biotech specializing in commercializing public- and private-sector IP.

 

Orchid BioSciences settled its patent lawsuit with Saint Louis University. In the settlement, Orchid acquired full ownership of the disputed patent, which is for SNP-based detection of genetic diseases and sequence variations.

 

TIGR scientists announced completion of the map for the Streptococcus agalactiae genome, which can cause a life-threatening infection in newborns, pregnant women, and chronically ill people.

 

Life sciences marketing and consulting firm Krug Consulting Group, run by former-InforMaxer Jane Krug, has opened new offices in Baltimore, Md.

 

Applied Biosystems and Myriad Proteomics joined in a collaboration to develop new proteomics technologies using ABI’s instruments as the major platform to work from.

 

SurroMed, based in Mountain View, Calif., was awarded an SBIR from the NCI to support development of the company’s affinity mass tag technologies to be used with mass spec instruments.

 

Psychiatric Genomics joined forces with the Harvard Brain Tissue Resource Center in an agreement to study schizophrenic and bipolar disorders using gene expression analysis tools.

 

The Belgian functional genomics firm Devgen announced that it acquired the assets of Elegene, including image acquisition tools and a library of CNS disease models. Devgen expects the technology to further its work with C. elegans.

 

High Throughput Genomics of Tucson, Ariz., entered into a screening technology supply agreement with drug-discovery firm Celgene.

 

BioAccelerator, the bioscience incubator that just started up in Fairfax County, Va., claimed as one of its first clients OriGenel, which works in outsourcing bioinformatics R&D projects.

 

San Diego’s Illumina teamed up with the University of Cambridge to provide SNP genotyping services on samples from a collection at the university’s Institute for Medical Research.

 

Cellular Genomics opened a new facility for small-molecule drug discovery in Branford, Conn. The facility is 9,000 square feet and will house technologies for high-throughput screening and structure-based drug design.

 

Agilent Technologies and IBM will work together to build an informatics system to accelerate drug discovery and development for life sciences customers.

 

Austin, Texas-based Ambion won a $1.6 million SBIR grant from the NIH to continue development of its RNA amplification technology, which could improve DNA microarray results.

 

Johns Hopkins University researchers announced the discovery of what they call “jumping genes,” which move from one chromosome to another, rearranging the genome. The freshly inserted regions were shown in many cases to delete chunks of DNA wherever they arrived.

 

Serenex, a Durham, NC-based functional proteomics company, raised more than $15 million in a series B financing round. Intersouth Partners led the funding, which included new investors Lilly Bio- Ventures and Seaflower Ventures as well as previous investor Mediphase Venture Partners.

 

After doing all it could with short-tandem-repeat analysis, the New York City medical examiner’s office last month began using Orchid’s SNP-IT and SNPstream UHT technologies to try to identify the most degraded remains of victims of the Sept. 11 World Trade Center attack. Orchid’s forensics unit, Cellmark in Dallas, will use secret technology developed at the company’s Princeton headquarters.

 

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.